Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Hepregen Corporation and The Hamner Institutes for Health Sciences Announce Research Partnership

Published: Tuesday, August 13, 2013
Last Updated: Tuesday, August 13, 2013
Bookmark and Share
Agreement provides opportunity to collaborate on research supporting next generation in vitro micro-liver analysis associated with pharmaceutical and chemical product development.

Hepregen Corporation and The Hamner Institutes for Health Sciences announced execution of an agreement that provides for a research partnership between the two entities. The research effort will be led by Dr. Edward LeCluyse, Associate Investigator at The Hamner, and Dr. Michael Holsapple, newly appointed Vice President of Toxicology Product Development at Hepregen, along with Mr. Jack McGeehan, Hepregen’s Vice President of Operations. The partnership will focus on research and development efforts aimed at defining: (1) basic concepts regarding the potential for new micro-liver products and (2) new applications and assay methodologies for Hepregen’s existing micro-liver products that are already transforming pharmaceutical product development.

“This Hamner-Hepregen partnership brings together outstanding teams of scientists from both organizations, creating a cooperative effort that will yield new knowledge about how best to utilize Hepregen’s micro-liver products for safety testing associated with pharmaceutical and chemical product development,” stated Dr. Vincent Zurawski, Hepregen’s chief executive officer.

Dr. William Greenlee, President and CEO of The Hamner also commented, “This research partnership provides yet another example of The Hamner’s ability to attract and partner with high quality commercial enterprises that share our organization’s commitment to advancing human health. We look forward to working with Hepregen in our mutual quest to provide advanced, next generation predictive health tools to the pharmaceutical, chemical and related industries.”

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,200+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

QPS Holdings and Hepregen Corporation Announce Commercial Partnership
The agreement provides co-promotion, marketing and sales of services utilizing Hepregen’s proprietary HepatoPac products.
Thursday, May 30, 2013
Hepregen Announces Issuance of its First Patent
The patent protects manufacturing methods of Hepatopac and related products.
Tuesday, May 28, 2013
Scientific News
Salford Lung Study - The First Real World Clinical Trial
In this podcast, we learn about the Salford Lung Study and its potential to revolutionize the way we assess new drugs and treatments around the world.
Editing Gene Mutations in Anemia
Researchers successfully use a new gene editing strategy to correct mutations that cause a form of anemia.
Nanomedicine Aims to Improve HIV Drug Therapies
New research aims to improve the administration and availability of drug therapies to HIV patients using nanotechnology.
Observing Direct Inheritance of Gene-Silencing RNA
Research has allowed for the observation of double-stranded RNA molecule being passed from parent to offspring in roundworms.
Fighting Cancer with Immune Response
New treatment elicits two-pronged immune response that destroys tumors in mice.
First Entirely 3D-printed Organ-on-a-Chip with Integrated Sensors
New approach to manufacturing may allow researchers to rapidly design organs-on-chips that match the properties of a specific disease or individual patient's cells.
Nanoparticles Offer Promising Platform for Flavivirus Treatment
New nanoparticle effectively vaccinated mice against one dengue strain and could be created to target all four.
Study Finds Key Regulator in Pulmonary Fibrosis
Researchers identify an enzyme that could open the way to therpies for chronic fatal lung disease.
Signaling Pathway Could Be Key to Improved Osteoporosis Treatment
Inhibition of SIK2 enzyme both stimulates bone formation and reduces bone breakdown in animal model.
Ovarian Cancer Insight
Study showed tumours release cytokines to attract macrophages, which secrete growth factors that in turn promote tumour growth.

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,200+ scientific videos